How Polynucleotides Work: The Cellular Mechanism Explained
- Oct 2, 2025
- 7 min read
Updated: 1 day ago
Here's a question I get asked constantly in clinic: "Are polynucleotides just another filler?"
I understand why people ask it. The aesthetic industry generates so much noise around new treatments that patients have learned, rightly, to be sceptical. Every season brings something that claims to be revolutionary. Most aren't. Polynucleotides genuinely are.
Let me explain what is actually happening when polynucleotides, also known as PDRN or polydeoxyribonucleotides, are injected into your skin. Not the marketing version. The real version.
What polynucleotides actually are
Polynucleotides are long-chain DNA fragments, typically extracted and purified from salmon sperm cells. Before that provokes any reaction, let me explain why this is entirely logical. Salmon DNA shares a remarkably high structural similarity with human DNA. These fragments are not cells, not organisms, not anything biologically active in their own right when extracted. They are purified chains of nucleotides that our own cellular machinery knows exactly how to process.
The key distinction from almost every other injectable treatment is this: polynucleotides do not add volume. They do not fill a space. They communicate directly with your skin cells, triggering a biological cascade that instructs those cells to do what they did when you were younger. This is molecular signalling. Not injury, not filler. Biology in action.
A 2025 comparative review published in PMC confirms that PDRN selectively activates the adenosine A2A receptor, a process that modulates inflammation, stimulates angiogenesis, and enhances collagen production in dermal fibroblasts. The evidence base for this mechanism spans decades of research.
How polynucleotides work: the biological timeline
This is where it gets genuinely fascinating. What follows is what is actually happening in your skin from the moment of injection through to visible results.
Hours 1 to 12: dispersal
The polynucleotide gel spreads through the dermis. You'll notice small raised blebs at the injection points. These are purely a distribution pattern, the product settling into the tissue. There is no aesthetic change yet, and that is exactly as it should be. This treatment rewards patience.
Days 1 to 7: enzymatic breakdown
Your own endogenous DNase enzymes begin to break the long polynucleotide chains into smaller fragments. This is not the treatment being destroyed. This is the treatment being activated. The breakdown is what creates the bioactive nucleotide fragments that drive everything that follows. It is a sustained-release mechanism that nature designed.
Days 3 to 14: A2A receptor binding
Here is the mechanism that separates polynucleotides from every injury-based collagen treatment. The smaller DNA fragments bind to adenosine A2A receptors on the surface of dermal fibroblasts, the cells responsible for producing collagen and elastin. This binding triggers those fibroblasts to switch on the genes responsible for structural protein production.
Research published in PMC confirms that this A2A receptor activation simultaneously reduces inflammatory infiltration, promotes fibroblast differentiation and maturation, and upregulates VEGF to support new blood vessel formation. It is a coordinated biological response, not a blunt injury signal.
This distinction matters enormously. Traditional collagen-stimulating treatments such as radiofrequency, lasers, and chemical peels work by creating controlled tissue damage. The body responds to that damage by producing collagen as part of a wound-healing response. The collagen produced this way is structurally adequate but not optimal. Scar-like. Disorganised. Polynucleotides bypass injury entirely. The collagen produced is structured, organised, and functionally equivalent to what your fibroblasts produce naturally.
Weeks 1 to 4: cellular cascade
The fibroblasts that have been activated begin increasing their protein synthesis. Growth factors released during this process stimulate surrounding cells, amplifying the effect well beyond the direct injection points. This is why treatment outcomes often feel more comprehensive than the treatment area.
Weeks 4 to 12: tissue remodelling
New collagen and elastin form structured networks in the dermis. Hyaluronic acid is produced and integrates naturally into the extracellular matrix. Skin visibly thickens, firms, and smooths. This is not swelling. This is genuine structural change at the dermal level.
Three benefits your practitioner may not mention
The treatment timeline above covers what most people are told. But there are three additional mechanisms worth understanding, because they are what place polynucleotides in a completely different category to skin boosters and hydrators.
Reactivating senescent fibroblasts
As we age, fibroblasts do not die. They enter a state of senescence, essentially retirement, where they stop responding to normal biological signals. They are still present in the dermis but contribute nothing to collagen production.
Research published in PLOS ONE demonstrated that PDRN treatment mitigates cellular senescence induced by UVB and oxidative stress, restoring migration capacity and cellular activity in senescent skin cells. A related PMC study found that PDRN's effects on human corneal fibroblast growth were particularly consistent and reproducible in donors over 60 years of age, directly suggesting a selective benefit in senescent cells. Polynucleotides essentially bring these retired cells back to work.
UV damage repair at the cellular level
The salvage pathway activated by polynucleotides does not only stimulate collagen production. It also supports the repair of cyclobutane pyrimidine dimers, the specific DNA lesions caused by UVB radiation. If you have years of sun exposure, polynucleotides are not merely treating the surface consequence of that damage. They are addressing it at the molecular level.
Reducing the inflammatory environment that accelerates ageing
Chronic low-grade inflammation, what longevity scientists call inflammaging, is one of the primary drivers of accelerated skin ageing. It degrades collagen, impairs fibroblast function, and creates an environment hostile to tissue repair. Polynucleotides actively suppress the pro-inflammatory cytokines driving this process. The skin you treat is also the skin you protect going forward.
How polynucleotides compare to other collagen treatments
This is the question I find most useful to answer honestly. Not every treatment is right for every patient. Here is how polynucleotides sit alongside the alternatives:
Polynucleotides | Profhilo | RF / Lasers / Peels | |
Mechanism | Molecular signalling via A2A receptor | Hyaluronic acid bio-remodelling | Controlled tissue injury |
Collagen type produced | Organised, structural | Stimulated via HA spread | Scar-response collagen |
Downtime | Minimal | Minimal | Variable, often significant |
Inflammation involved | Anti-inflammatory | Low | High by design |
UV repair benefit | Yes | No | No |
Senescent cell effect | Yes | No | No |
Best for | Skin quality, texture, regeneration | Volume, hydration, laxity | Surface resurfacing, pigmentation |
Profhilo and polynucleotides complement each other beautifully and I frequently recommend both in a phased approach. They address different biological mechanisms and different patient concerns.
What to expect: results timeline
Polynucleotides are not an instant result treatment. Patients who understand the biology embrace this. The timeline reflects real cellular activity, not swelling.
Weeks 1 to 4: Subtle improvement in skin texture and hydration as initial fibroblast activity begins
Weeks 4 to 8: Noticeable firmness; fine lines begin to smooth as new collagen integrates
Weeks 8 to 12: Peak remodelling; skin looks noticeably healthier, firmer, and more luminous
Months 3 to 6: Sustained improvement continues even as the polynucleotide itself metabolises, because the cells it activated remain in a heightened state of function
A standard course is two sessions, four weeks apart. Maintenance is typically one session every six to twelve months depending on skin condition and age.
Who is a good candidate for polynucleotides in Kent?
Polynucleotides work for a wide range of patients and concerns. They are particularly effective for:
Early to moderate skin laxity, loss of firmness, and fine lines
Dull, dehydrated skin that lacks vitality
Skin quality concerns rather than volume loss
Sun damage and the consequences of photoageing
Patients who want biological regeneration rather than volume addition
Combination with other treatments as a regenerative foundation
Any patient who prefers a treatment with minimal downtime and no risk of looking overdone
They are not the right choice for patients whose primary concern is significant volume loss or deep structural change. Those situations require a different conversation, often involving dermal filler or threads.
Frequently asked questions
Do polynucleotides hurt? Discomfort is minimal. A topical anaesthetic is applied beforehand. The product itself contains a viscous gel formulation that makes placement comfortable. Most patients describe awareness of the injections rather than pain.
Are polynucleotides the same as Profhilo? No. They work via completely different mechanisms. Profhilo is a hyaluronic acid bio-remodeller that hydrates and stimulates collagen through a spreading mechanism. Polynucleotides are DNA-derived fragments that activate A2A receptors to trigger a cellular regeneration cascade. They complement each other and are often used together.
Is the salmon DNA source safe? Yes. The polynucleotides used in aesthetic medicine are extensively purified and undergo rigorous quality control. Salmon DNA has a high structural compatibility with human DNA, and decades of clinical use have demonstrated an excellent safety profile with minimal adverse reactions.
Can polynucleotides be combined with other treatments? Absolutely. They work synergistically with Profhilo, microneedling, and red light therapy. Many patients use them as a regenerative foundation alongside other treatments in a personalised protocol.
How is this different from PRP? PRP, or platelet-rich plasma, uses your own growth factors to stimulate repair. Polynucleotides activate a specific receptor pathway that drives a more targeted, sustained collagen-signalling cascade. Both have merit. They work differently and suit different patients. We discuss both options at consultation.
Key takeaways
I have been in aesthetic medicine long enough to have seen trends come and go. I know the difference between something the industry is excited about and something that the science supports. Polynucleotides are the latter.
The A2A receptor mechanism, the senescent fibroblast reactivation, the UV damage repair, and the anti-inflammatory effect on the ageing skin environment are not marketing claims. They are documented, replicated, peer-reviewed mechanisms. For a cardiac nurse who has spent her career demanding that evidence, that matters more than any before and after photograph.
What I offer at Juvenology is a treatment that works with your biology rather than against it. No injury required. No inflammatory cascade to manage. Just a precise, evidence-based intervention that asks your skin to do what it already knows how to do, just with the resources and signals it needs to do it well.
"In cardiac nursing, I learned to trust what the science shows over what the industry claims. Polynucleotides are the treatment that has earned that trust most completely. The biology is real, the results follow the biology, and that is exactly how medicine should work." Nurse Marina, Juvenology Clinic
About the author
Nurse Marina is an aesthetic nurse specialist based in Maidstone, Kent, with over 25 years of nursing experience including six years in cardiac care at KIMS Hospital. She specialised at Spencer Private Hospitals before founding Juvenology, a longevity-focused aesthetics clinic combining regenerative medicine with evidence-based practice.
Marina is NMC Registered, BACN Member, JCCP Verified, ACE Group Registered, and a Member of the Royal College of Nursing.